Apyx Medical CORP 10-Q quarterly reports

Apyx Medical Corporation reported increased revenue and improved gross margins for the second quarter of 2026, but continued to incur net losses and cash outflows from operations, highlighting ongoing financial challenges.

Apyx Medical reports a 32.4% increase in Q1 2026 revenue to $12.5 million, driven by strong growth in its Surgical Aesthetics segment.

Apyx Medical Corporation reported reduced net losses and increased Surgical Aesthetics sales in Q3 2025, driven by the AYON Body Contouring System launch, while navigating OEM segment declines and ongoing litigation.

Apyx Medical Corporation reported a significant reduction in net loss for Q2 2025, driven by substantial cost-cutting measures, despite a slight revenue decline, and announced the commercial launch of its AYON Body Contouring System.

Apyx Medical's Q1 2025 results show a mixed performance with growth in the Advanced Energy segment partially offset by a decline in OEM sales, while the company implements cost-saving measures to improve profitability.

Apyx Medical Corporation's Q3 2024 results show a decrease in revenue and a net loss, prompting a restructuring and cost-saving initiative.

Apyx Medical Corporation's Q2 2024 results show a decrease in revenue and gross profit compared to the same period last year, alongside increased legal expenses and a net loss.

Apyx Medical's first quarter 2024 revenue decreased by 15.6% year-over-year, primarily due to a decline in domestic sales of Advanced Energy products.